Managers / Q3 2022 · view latest →
Rye Brook Capital LLC
CIK 0001844147 · 777 WEST PUTNAM AVE, SUITE 300, GREENWICH, CT, 06830 · 203-542-2822
Summary
Rye Brook Capital LLC reported $137M in U.S.-listed holdings across 21 positions for Q3 2022.
The portfolio is heavily concentrated: QQQ alone accounts for 29.1% of reported value.
Compared with Q2 2022, the fund opened 1 new position and exited 2.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- ETP · 87.1% · $119M
- Common Stock · 8.4% · $12M
- REIT · 4.5% · $6M
Quarter-over-Quarter Changes full breakdown →
vs Q2 2022 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| VMIVALMONT INDUSTRIES | NEW | +4.0K | 4.0K | +$1M | $1M |
| TSLATESLA INC | ADDED | +1.0K | 1.8K | −$55,000 | $477,000 |
| USOUNITED STATES OIL FUND LP | SOLD OUT | −40.0K | 0 | −$3M | $0 |
| KBAKRANESHARES BOSERA MSCI CHIN | SOLD OUT | −12.7K | 0 | −$493,000 | $0 |
| KRANESHARES CSI CHINA INTERN | TRIMMED | −98.7K | 40.1K | −$4M | $988,000 |
| IBBISHARES NASDAQ BIOTECHNOLOGY | TRIMMED | −56.1K | 40.3K | −$7M | $5M |
| ETHEGRAYSCALE ETHEREUM TRUST | ADDED | +84.9K | 276.9K | +$1M | $3M |
| AAPLAPPLE INC | TRIMMED | −1.0K | 1.5K | −$138,000 | $213,000 |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q3 2022
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $108M | 28 | Apr 29, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $107M | 27 | Jan 27, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $192M | 31 | Oct 21, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $96M | 24 | Jul 23, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $80M | 20 | Apr 16, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $83M | 29 | Feb 3, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $69M | 19 | Oct 22, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $76M | 25 | Jul 22, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $171M | 28 | Apr 11, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $196M | 30 | Jan 30, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $141M | 28 | Oct 10, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $212M | 26 | Jul 24, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $164M | 27 | Apr 21, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $154M | 23 | Jan 6, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $137M | 21 | Nov 3, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $164M | 22 | Jul 21, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $253M | 32 | Apr 28, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $390M | 29 | Jan 12, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $142M | 27 | Oct 4, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $141M | 27 | Jul 19, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $137M | 28 | Apr 9, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $115M | 24 | Feb 3, 2021 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.